Loading
Inobrodib is an experimental pill from CellCentric, in phase 3 trials for relapsed or refractory multiple myeloma.
Inobrodib (CCS1477) is a small molecule, oral from CellCentric. Blocks the bromodomain of p300 (EP300) and CBP (CREBBP), two proteins that switch on genes, lowering the activity of cancer genes including MYC and IRF4. A phase 3 study with pomalidomide and dexamethasone (NCT07772024, started August 2026) and a phase 2 study (NCT07096778) are recruiting in relapsed or refractory myeloma; earlier studies covered blood cancers (NCT04068597) and advanced solid tumours (NCT03568656). The company says the FDA granted Fast Track and orphan drug designations in relapsed or refractory myeloma.
1.Inobrodib slips into a pocket on EP300.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Inobrodib" OR ABSTRACT:"Inobrodib" OR TITLE:"CCS1477" OR ABSTRACT:"CCS1477") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Inobrodib, not a curated reading list.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/